search
Back to results

Non-Invasive MOnitoring in Transcathether Aortic Valve Implantation (NIMO-TAVI)

Primary Purpose

Aortic Valve Disease

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
HemoSphere ClearSight Module
Sponsored by
University of Basel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Aortic Valve Disease focused on measuring Transcatheter aortic valve implantation, hemodynamic parameter

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: • Adult patients (>18 years old) with severe aortic stenosis undergoing elective TAVI. Exclusion Criteria: Emergency indication for TAVI Severe tricuspid regurgitation Severe mitral stenosis or severe regurgitation Invasive right heart catheterization impossible Dependency on right ventricle pacing immediately after TAVI implantation Vulnerable subjects Known or suspected non-compliance, drug or alcohol abuse Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation affecting this study Previous enrolment into the current investigation

Sites / Locations

  • University Hospital BaselRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Hemodynamic Monitoring

Arm Description

Simultaneous measurement of hemodynamic parameters such as Cardiac output, cardiac index and blood pressure with invasive right heart catheterization and non-invasive application of the Clearsight Finger Cuff.

Outcomes

Primary Outcome Measures

Cardiac Output
Cardiac Output (CO in L/min)
Cardiac Index
Cardiac Index (CI in L/min/m2)
Systolic blood pressure
systolic blood pressure (sBP in mmHg)
Diastolic blood pressure
diastolic blood pressure (dBP in mmHg)

Secondary Outcome Measures

Full Information

First Posted
April 4, 2023
Last Updated
April 30, 2023
Sponsor
University of Basel
search

1. Study Identification

Unique Protocol Identification Number
NCT05840757
Brief Title
Non-Invasive MOnitoring in Transcathether Aortic Valve Implantation
Acronym
NIMO-TAVI
Official Title
Non-Invasive MOnitoring in Transcathether Aortic Valve Implantation - A Single-center, Prospective, Interventional Study With the ClearSight® Finger Cuff
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 31, 2023 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Basel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) minimal evidence is available for invasive hemodynamic monitoring and no evidence for tools able to measure traditionally invasive parameters non-invasively for peri-procedural guidance and post-interventional management. The aim of this study is to evaluate the effectiveness and safety of a non-invasive hemodynamics monitoring tool called ClearSight for monitoring during TAVI procedures compared with standard invasive measurements.
Detailed Description
In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) minimal evidence is available for invasive hemodynamic monitoring and no evidence for tools able to measure traditionally invasive parameters non-invasively for peri-procedural guidance and post-interventional management. The aim of this study is to evaluate the effectiveness and safety of a non-invasive hemodynamics monitoring tool called ClearSight for monitoring during TAVI procedures compared with standard invasive measurements. The ClearSight monitoring system works non-invasively by utilizing an inflatable finger cuff which adjusts automatically to measure the arterial blood pressure which enables the calculation of parameters such as cardiac output or index. Multiple studies have demonstrated the reliability and feasibility of continuous non-invasive monitoring, in different settings, however it was never performed in patients undergoing TAVI. The ClearSight monitoring system will be directly compared to invasive measurements of hemodynamic parameters during the procedure. In addition, information regarding baseline hemodynamics and its changes during/after procedure may give important information on peri- and post-procedural management and short-term outcomes and discharge planning. A tool, providing this information non-invasively with the same accuracy might result in a major improvement in daily practice..

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Disease
Keywords
Transcatheter aortic valve implantation, hemodynamic parameter

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hemodynamic Monitoring
Arm Type
Other
Arm Description
Simultaneous measurement of hemodynamic parameters such as Cardiac output, cardiac index and blood pressure with invasive right heart catheterization and non-invasive application of the Clearsight Finger Cuff.
Intervention Type
Device
Intervention Name(s)
HemoSphere ClearSight Module
Intervention Description
The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
Primary Outcome Measure Information:
Title
Cardiac Output
Description
Cardiac Output (CO in L/min)
Time Frame
During aortic valve implantation which generally takes about 40mins
Title
Cardiac Index
Description
Cardiac Index (CI in L/min/m2)
Time Frame
During aortic valve implantation which generally takes about 40mins
Title
Systolic blood pressure
Description
systolic blood pressure (sBP in mmHg)
Time Frame
During aortic valve implantation which generally takes about 40mins
Title
Diastolic blood pressure
Description
diastolic blood pressure (dBP in mmHg)
Time Frame
During aortic valve implantation which generally takes about 40mins

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Adult patients (>18 years old) with severe aortic stenosis undergoing elective TAVI. Exclusion Criteria: Emergency indication for TAVI Severe tricuspid regurgitation Severe mitral stenosis or severe regurgitation Invasive right heart catheterization impossible Dependency on right ventricle pacing immediately after TAVI implantation Vulnerable subjects Known or suspected non-compliance, drug or alcohol abuse Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation affecting this study Previous enrolment into the current investigation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Nestelberger
Phone
004161265
Email
kardiologie@usb.ch
Facility Information:
Facility Name
University Hospital Basel
City
Basel
State/Province
BS
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Nestelberger
Phone
0612652525
Email
herzzentrum@usb.ch

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Non-Invasive MOnitoring in Transcathether Aortic Valve Implantation

We'll reach out to this number within 24 hrs